Form 4: Neumora Therapeutics Executive Receives Option Repricing, Acquires New Options

Paul L. Berns, a director and officer of Neumora Therapeutics, received an option repricing and new stock options on February 13, 2025, subject to stockholder approval.

Summary

• Paul L. Berns, Chief Executive Officer and Chairman of the Board of Neumora Therapeutics, Inc., filed a Form 4 on February 18, 2025, detailing changes in beneficial ownership.
• On February 13, 2025, Berns received new stock options and had existing options repriced, contingent on stockholder approval.
• The new options have an exercise price of $1.69 per share.
• The repricing affects options with original exercise prices of $4.63, $6.36, and $18.07.
• Vesting schedules for the options generally involve 25% vesting on the first anniversary of the Vesting Commencement Date, with the remainder vesting monthly over the following 36 months.
• The repricing is subject to Berns remaining in service to the Issuer through August 13, 2026.

Sentiment

Score: 6

Explanation: The document is neutral. It simply reports changes in beneficial ownership related to stock options. The repricing could be seen as positive for incentivizing management, but also potentially negative if it suggests past underperformance or retention concerns.

Positives

• The option repricing and grant could incentivize Paul L. Berns to remain with Neumora Therapeutics and drive company performance.
• The lower exercise price of $1.69 makes the options more valuable to Berns.

Negatives

• The option repricing is contingent on stockholder approval, which introduces uncertainty.
• The repricing is also contingent on Berns remaining in service through August 13, 2026, which may indicate concerns about retention.

Risks

• Failure to obtain stockholder approval for the option repricing would void the changes.
• If Paul L. Berns leaves Neumora Therapeutics before August 13, 2026, the repricing may be voided.
• Option repricing can be viewed negatively by shareholders if not properly justified, potentially leading to dissatisfaction.

Future Outlook

The option repricing is contingent on stockholder approval and Paul L. Berns' continued service through August 13, 2026.

Industry Context

Option repricing is a common practice to incentivize executives, particularly in volatile market conditions or when a company's stock price has declined. It aims to re-align executive compensation with company performance and retain key personnel. The pharmaceutical industry is highly competitive, and retaining key executives is crucial for the success of drug development and commercialization efforts.

Comparison to Industry Standards

• Option repricing is a fairly common practice in the pharmaceutical industry, especially for companies that have experienced a decline in stock price.
• Companies like Biogen and Amgen have used similar strategies to retain key executives and align their interests with shareholders.
• The vesting schedules described are fairly standard, with a four-year vesting period being typical for executive stock options.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the new stock options and the repricing of existing options.
• Employees may be impacted by the signal sent by the company regarding executive compensation and retention.
• The repricing could incentivize management to improve company performance, benefiting all stakeholders.

Next Steps

• Neumora Therapeutics' stockholders must approve the option repricing.
• Paul L. Berns must remain in service to the Issuer through August 13, 2026, for the repricing to remain valid.

Key Dates